Long-term safety and effectiveness of eculizumab in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: a 2-year interim analysis of post-marketing surveillance in Japan

BACKGROUND: The terminal complement C5 inhibitor eculizumab is approved in Japan for relapse prevention in aquaporin-4 antibody-positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD) and is undergoing mandatory post-marketing surveillance (PMS) of clinical use. OBJECTIVES: The objective of...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakashima, Ichiro, Nakahara, Jin, Yokote, Hiroaki, Manabe, Yasuhiro, Okamura, Kazumi, Hasegawa, Kou, Fujihara, Kazuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333632/
https://www.ncbi.nlm.nih.gov/pubmed/37441104
http://dx.doi.org/10.1177/17562864231181177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333632/
https://www.ncbi.nlm.nih.gov/pubmed/37441104
http://dx.doi.org/10.1177/17562864231181177

Ejemplares similares